1 completed, 1 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
Follow Kang Stem Biotech Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of FURESTEM-AD Inj. for Moderate to Severe Atopic Dermatitis (AD) FURESTEM-AD® inj. 5.0 X 10^7 cells/1.5 mL, Placebo - Dermatitis, Atopic | Phase 3 | Unknown | Kang Stem Biotech Co., Ltd. | 308 | 2021-06-29 | 2021-08-13 |
| Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD) FURESTEM-AD Inj., Placebo - Atopic Dermatitis | Phase 3 | Completed | Kang Stem Biotech Co., Ltd. | 197 | 2018-04-25 | 2019-09-12 |
Dermatitis, Atopic (2) · Dermatitis (1) · Eczema (1) · Skin Diseases (1)
South Korea (2)
Bakrin Yoo, professor (1) · Chanho Na, professor (1) · Cheonuk Park, professor (1) · Donghoon Lee, professor (1) · Hyunchang Ko, professor (1) · Jeongeun Kim, professor (1) · Jihyun Lee, professor (1) · Jiyoung Ahn, professor (1) · Jooyeon Ko, professor (1) · Minkyung Shin, professor (1) · Sanghyun Cho, professor (1) · Sanguk Son, professor (1) · Taeyoung Han, professor (1) · Yangwon Lee, professor (1) · Yeonglib Park, professor (CI) (1)